Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no animal models that exactly reproduce human liver fibrosis that can be used to better understand the mechanisms of its regression and identify new targets for treatment and therapeutic approaches. On the other hand, mesenchymal stem cells (MSC) have experimentally demonstrated fibrosis regression effects, but it is necessary to have an animal model of advanced liver fibrosis to evaluate the effect of these cells. The aim of this work was to establish a protocol for the induction of advanced liver fibrosis in rats using thioacetamide (TAA), which will allow us to perform trials using MSC as a possible therapy for fibrosis regression. For this purpose, we selected 24 female rats and grouped them into three experimental groups: the control group (G-I) without treatment and groups II (G-II) and III (G-III) that received TAA by intraperitoneal injection for 24 weeks. Then, adipose mesenchymal stem cells (ASCs) were infused intravenously. Groups G-I and G-II were sacrificed 7 days after the last dose of ASC, and G-III was sacrificed 8 weeks after the last ASC infusion, all with xylazine/ketamine (40 mg/kg). The protocol used in this work established a model of advanced hepatic fibrosis as corroborated by METAVIR tests of the histological lesions; by the high levels of the markers α-SMA, CD68, and collagen type I; by functional alterations due to elevated markers of the hepatic lesions; and by alterations of the leukocytes, lymphocytes, and platelets. Finally, transplanted cells in the fibrous liver were detected. We conclude that TAA applied using the protocol introduced in this study induces a good model of advanced liver fibrosis in rats.
Peru has become one of the countries with the highest mortality rate from the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. To investigate early transmission event and genomic diversity of SARS-CoV-2 isolates circulating in Peru, we analyzed a total of 3472 SARS-CoV-2 genomes, from which 149 ones were from Peru. Phylogenomic analysis revealed multiple and independent introductions of the virus mainly from Europe and Asia. In addition, we found evidence for community-driven transmission of SARS-CoV-2 as suggested by clusters of related viruses found in patients living in different Peru regions.
Background and Aim: Ribonucleic acid viruses remain latent in different cell types, including mesenchymal stem cells; however, the distemper virus remains undetected in these cells. This study aimed to determine whether adipose stem cells (ASCs) from dogs with distemper disease are infected with the canine morbillivirus (CM). Materials and Methods: Twelve dogs with the neurological phase of the disease and who were positive for CM by reverse transcription polymerase chain reaction (RT-PCR), were studied. ASCs from adipose tissue of the lesser omentum of these infected dogs were isolated and characterized. Direct fluorescence was used to detect the viral antigen in cell cultures. Flow cytometry and RT-PCR identified detectable quantities of the virus in two cultures, while electron microscopy confirmed the CM particles within ASCs. Results: This study revealed that ASCs of the omentum of dogs with distemper disease can be infected with CM, indicating their possible involvement in this virus latency and persistence. This suggests that its detection should be considered within the quality control process of stem cells intended for regenerative medicine. Conclusion: To the best of our knowledge, this is the first study that demonstrates that omentum ASCs from dogs with distemper disease can be infected with CM and may be involved in viral latency or persistence. Our study also suggests that the detection of CM should be considered within the quality control process of stem cells intended for regenerative medicine.
Introduction: There is no specific therapy for triple‐negative breast cancer (TNBC), and the recurrence rate is high. Cancer stem cells (CSCs) play an important role in cancer chemoresistance and metastasis, but there is no consensus marker in this type of cancer. The aim of this study was to identify CSC biomarkers in the plasma secretome of TNBC patients. Methods: CD44+/CD24− CSCs were isolated from MDA‐MB‐436 and MDA‐MB‐231 (ATCC) lines by magnetic immunoselection. The extracellular vesicles (EVs) of CSCs were isolated by size exclusion chromatography (SEC) of conditioned medium (CM) without fetal bovine serum (FBS) and blood plasma from TNBC and healthy women. Tetraspanins CD9 and CD81 identified the EVs, while electron microscopy determined the morphology and tunable resistive pulse sensing (TRPS) established particle size. Luminex technology was used to determine the presence of L1 cell adhesion molecule (L1CAM), carbonic anhydrase IX (CA9), mesothelin, midkine, hepsin, kallikrein‐6 (KLK6), transglutaminase 2 (TGM2), aldehyde dehydrogenase 1a1 (ALDH1A1), epithelial cell adhesion molecule (EpCAM), and differentiation cluster 44 (CD44). Results: Particles of 0–200 nm in size were more frequent in CSC‐MDA‐MB‐436, while particles of 201–500 nm were more frequent in CSC‐MDA‐MB‐231. In blood plasma, the particle size was 150–250 nm in TNBC patients and 150–300 nm in healthy individuals. Particle concentrations were 1.3 × 10 10 in CSCs of the MDA‐MB‐231 (CSC‐MDA‐MB‐231) cell line and 3.8 × 10 7 in the MDA‐MB‐231 cell line (L‐MDA‐MB‐231). The concentration of CSCs in MDA‐MB‐436 was 2.7 × 10 8 compared to 9.4 × 10 7 in L‐MDA‐MB‐436. Midkine and CA9 were present in the EVs of both CSC lines and in the plasma of women with TNBC but absent in the blood plasma of healthy women. Midkine showed better statistical discrimination. Conclusions: The size and concentration of EVs are heterogeneous. Midkine and CA9 are produced by CSCs in women with TNBC and may be possible biomarkers of these cells in this tumour type.